Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
April 25, 2024 16:46 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on...
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
April 24, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has...
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
March 04, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global...
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
February 07, 2024 16:01 ET
|
Ascendis Pharma
Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4...
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life...
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
January 31, 2024 16:15 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday,...
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
January 31, 2024 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone...
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
January 29, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company...
Ascendis Pharma Introduces Vision 2030
January 07, 2024 17:45 ET
|
Ascendis Pharma
Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) --...
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023 16:15 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice...